TRANSFUSION—VOLUME 29 (1989)
Subject Index

In the subject index, the page number refers to the first page of the communication in which the subject is addressed rather than to the specific page on which the referenced key words can be found. An "L" in parenthesis following the page number indicates that the subject entry appeared in letters to the editor; an "E" in parenthesis indicates the subject was discussed in an editorial.

In Volume 29 (1989), Number One (January) contains pages 1–94; Number Two (February), pages 95–188; Number Three (March–April), pages 189–282; Number Four (May), pages 283–376; Number Five (June), pages 377–470; Number Six (July–August), pages 471–564; Number Seven (September), pages 565–658; Number Eight (October), pages 659–752; and Number Nine (November–December), pages 753–845.

A

AABB standards..95(E), 259, 261, 268, 750(L), 661(E), 829 (L), 821
AABB Scientific Think Tank 711
ABO
  antigens in platelet transfusion....384, 514
  removal of
    antibodies....135, 514
    antigens....514
  typing....84(L)
Acquired immune deficiency syndrome (AIDS)
  epidemiologic patterns 572
  incubation time estimates....672, 659(E)
  loss of FVIII inhibitor in....447
  transfusion associated....659(E), 672, 711
  transfusion effect on immune response 236
  transmission and donor history....276(L)
  T4 helper cells in....447
Adenosine triphosphate (ATP)....226
Adoptive immunotherapy 170, 711
ADSOL, see AS-3 red cell storage system
Adult T-cell leukemia/lymphoma....1(E)
AIDS, see acquired immune deficiency syndrome
AIHA, see autoimmune hemolytic anemia
Alanine aminotransferase (ALT) ..17, 277(L), 565(E), 750(L), 751(L)
Albumin
  preparation....629
  research opportunities....711
  storage in glass containers and aluminum contamination in....86(L)
Algorithms
  use in
    compatibility testing ....95(E)
    transfusion practice....298
Alloimmunization....328, 377(E), 379, 450, 654(L), 711
ALT, see alanine aminotransferase
Alternative pathway of complement activation....803
Aluminum contamination ....86(L)
Anemia
  aplastic....654(L)
  autoimmune hemolytic....191(E), 196
  hemolytic, associated with suprofen and tolmetin 638
  in blood donors....268
Animal model
  fetal sheep, gene transfer 812
  tumor cells in autologous donation....418
  ultraviolet irradiation....450
Antibody, general
  against steroid factors ....559(L)
  association between red cell and HLA antibodies....789
  association with *Morganella morganii* 549
  citrate-dependent, bromelin reactive ....278(L)
  clearance of coated cells 347
  comparison of LISS and PEG....686
  development after transplantation 396
  distribution among Chinese 337
  formation in blacks 505
  frequency in liver transplantation....396
  inhibition by EDTA ....84(L)
  monoclonal antibodies
    and AIHA....191(E), 196
    impact in blood group serology 58, 340
  removal by immunoadsorbents 135
  research opportunities 711
Antibody, specific
  anti-A ....84(L), 135
  anti-A2M 2 337
  anti-B 135
  anti-Bak^a 129
  anti-c 421, 620
  anti-C 620
  anti-D 620
  anti-e 620
  anti-E 421, 620
  anti-f ....276(L)
  anti-Fy^a....505, 620
  anti-Fy3 505
  anti-HLA....119, 654(L)
  anti-IgA$_2$ 337
  anti-In^b....465(L)
  anti-Jk^a 421
  anti-K 620
  anti-K1 549
  anti-Pl^{A1}....129
  anti-Rh6 ....276(L)
  anti-Rh46....798
  anti-U 508
  anti-UMC 794
Anticoagulants, effect on
  blood typing ....84(L)
  cryogel formation 165
Antigen, general
  ABO on platelets, removal of 514
  association with gram-negative bacteria....549
  classification of Miltenberger series 106
  Cromer-related 794, 803
  distribution
    among Chinese....337, 463(L)
    in Taiwan 233
    of platelet antigens in Koreans....708
  effect of ultraviolet irradiation 450
  frequency of neutrophil-specific antigens in Japanese....654(L)
  HLA and
    donor pool size in
      bone marrow transplantation 311
      plateletpheresis....285(E), 306
      platelet transfusion....193(E)
  quantitation of....103, 328
  research opportunities 711
  typing with
    modified anti-D ....559(L), 560(L)
    monoclonal antibodies....58, 340
Antigen, specific
  HLA antigens on
    platelets....139(E), 201, 285(E), 306, 328, 405
    red cells 544
  major histocompatibility complex....711, 789
  minor histocompatibility complex....789

TRANSFUSION—VOLUME 29 (1989)
Subject Index

In the subject index, the page number refers to the first page of the communication in which the subject is addressed rather than to the specific page on which the referenced key words can be found. An "L" in parenthesis following the page number indicates that the subject entry appeared in letters to the editor; an "E" in parenthesis indicates the subject was discussed in an editorial.

In Volume 29 (1989), Number One (January) contains pages 1–94; Number Two (February), pages 95–188; Number Three (March–April), pages 189–282; Number Four (May), pages 283–376; Number Five (June), pages 377–470; Number Six (July–August), pages 471–564; Number Seven (September), pages 565–658; Number Eight (October), pages 659–752; and Number Nine (November–December), pages 753–845.

A

AABB standards..95(E), 259, 261, 268, 750(L), 661(E), 829 (L), 821
AABB Scientific Think Tank 711
ABO
  antigens in platelet transfusion....384, 514
  removal of
    antibodies....135, 514
    antigens....514
  typing....84(L)
Acquired immune deficiency syndrome (AIDS)
  epidemiologic patterns 572
  incubation time estimates....672, 659(E)
  loss of FVIII inhibitor in....447
  transfusion associated....659(E), 672, 711
  transfusion effect on immune response 236
  transmission and donor history....276(L)
  T4 helper cells in....447
Adenosine triphosphate (ATP)....226
Adoptive immunotherapy 170, 711
ADSOL, see AS-3 red cell storage system
Adult T-cell leukemia/lymphoma....1(E)
AIDS, see acquired immune deficiency syndrome
AIHA, see autoimmune hemolytic anemia
Alanine aminotransferase (ALT) ..17, 277(L), 565(E), 750(L), 751(L)
Albumin
  preparation....629
  research opportunities....711
  storage in glass containers and aluminum contamination in....86(L)
Algorithms
  use in
    compatibility testing ....95(E)
    transfusion practice....298
Alloimmunization....328, 377(E), 379, 450, 654(L), 711
ALT, see alanine aminotransferase
Alternative pathway of complement activation....803
Aluminum contamination ....86(L)
Anemia
  aplastic....654(L)
  autoimmune hemolytic....191(E), 196
  hemolytic, associated with suprofen and tolmetin 638
  in blood donors....268
Animal model
  fetal sheep, gene transfer 812
  tumor cells in autologous donation....418
  ultraviolet irradiation....450
Antibody, general
  against steroid factors ....559(L)
  association between red cell and HLA antibodies....789
  association with *Morganella morganii* 549
  citrate-dependent, bromelin reactive ....278(L)
  clearance of coated cells 347
  comparison of LISS and PEG....686
  development after transplantation 396
  distribution among Chinese 337
  formation in blacks 505
  frequency in liver transplantation....396
  inhibition by EDTA ....84(L)
  monoclonal antibodies
    and AIHA....191(E), 196
    impact in blood group serology 58, 340
  removal by immunoadsorbents 135
  research opportunities 711
Antibody, specific
  anti-A ....84(L), 135
  anti-A2M 2 337
  anti-B 135
  anti-Bak^a 129
  anti-c 421, 620
  anti-C 620
  anti-D 620
  anti-e 620
  anti-E 421, 620
  anti-f ....276(L)
  anti-Fy^a....505, 620
  anti-Fy3 505
  anti-HLA....119, 654(L)
  anti-IgA$_2$ 337
  anti-In^b....465(L)
  anti-Jk^a 421
  anti-K 620
  anti-K1 549
  anti-Pl^{A1}....129
  anti-Rh6 ....276(L)
  anti-Rh46....798
  anti-U 508
  anti-UMC 794
Anticoagulants, effect on
  blood typing ....84(L)
  cryogel formation 165
Antigen, general
  ABO on platelets, removal of 514
  association with gram-negative bacteria....549
  classification of Miltenberger series 106
  Cromer-related 794, 803
  distribution
    among Chinese....337, 463(L)
    in Taiwan 233
    of platelet antigens in Koreans....708
  effect of ultraviolet irradiation 450
  frequency of neutrophil-specific antigens in Japanese....654(L)
  HLA and
    donor pool size in
      bone marrow transplantation 311
      plateletpheresis....285(E), 306
      platelet transfusion....193(E)
  quantitation of....103, 328
  research opportunities 711
  typing with
    modified anti-D ....559(L), 560(L)
    monoclonal antibodies....58, 340
Antigen, specific
  HLA antigens on
    platelets....139(E), 201, 285(E), 306, 328, 405
    red cells 544
  major histocompatibility complex....711, 789
  minor histocompatibility complex....789

platelet
ABO 384, 514
Bak^a 708, 711
PI^{A1} 405, 708, 711
PI^{A2} 708
Yuk^a 708, 711
Yuk^b 708, 711
red cell
c ..... 233, 464(L), 798
C 233, 798
Chido 803
Cromer-related 794, 803
C^w 798
D ..... 103, 559(L), 560(L), 798
D^u 103
e 798
E 798
f ..... 276(L)
Fy^a 233, 505
Fy^b 233, 505
K$_x$ 642, 711
Le^a ..... 463(L)
Le^b ..... 463(L)
Mi complex 106
P$_1$ 233
Rh6 ..... 276(L)
Rh17 798
Rh32 798
Rh44 798
Rh46 798
Rogers 803
s 233
S 233
Wr^b ..... 187(L)
U 794
UMC 794
Xg^a 233
white cell
NA1 ..... 654(L)
NA2 ..... 654(L)
NB1 ..... 654(L)
NB2 ..... 654(L)
NC1 ..... 654(L)
research opportunities 711
Antiglobulin test
compatibility testing ..... 95(E), 99
direct
positive
drug induced 638
in HIV-infected persons ..... 465(L)
in liver transplantation 396
with vancomycin 23
indirect
LISS 686
PEG ..... 218, 686, 750(L)
Antithrombin III concentrate 148, 711
Apheresis
collection of PBSC 323, 552
techniques, hollow membrane device 341
therapeutic, use in hypercholesterolemia 341
reactions in ..... 97(E), 424
Appreciation of service 200
Arachis hypogaea 635
Assay
alanine aminotransferase 17
Borrelia burgdorferi 581
CMV antibody ..... 830(L)
copper sulfate screening 259, 261
enzyme-linked immunoassay ..... 3(E)
flow cytometry
immunoglobulin class 549
white cell quantification 651
HIV-1 antibody ..... 3(E), 75, 78, 119, 148, 572
HTLV-1 antibody ..... 1(E), 7, 372(L)
IgA ..... 464(L)
immunoblot 106
mixed lymphocyte culture 41
monitoring plasmapheresis ..... 561(L)
monocyte monolayer ..... 465(L)
paternity testing, restriction fragment length polymorphism mapping 477
platelet
compatibility testing ..... 193(E), 201
monitoring system ..... 561(L)
typing 708
red cell
antibody detection, flow cytometry 549, 642
Western blot ..... 3(E), 7
white cell quantification
flow cytometry 651
propidium iodide staining 651, 774
ATP, see adenosine triphosphate
Attitude theory in donors 401
Audits, transfusion ..... 139, 471(E), 473
Authors' instructions, detailed 88
Authorship ..... 665(E)
Autoimmune hemolytic anemia (AIHA), role of monoclonal antibodies in ..... 191(E), 196
Autologous donations
collection facility, regulations for ..... 661(E)
comparison with homologous ..... 373(L), 821, 829(L)
crossover of ..... 373(L), 661(E), 821, 829(L)
discarding of 743
in Italy ..... 829(L)
intraoperative salvage ..... 661(E)
labeling of ..... 661(E)
preoperative 677
postoperative salvage ..... 661(E)
red cell mass in ..... Good
release of ..... 661(E)
research opportunities in 711
screening for
alanine aminotransferase ..... 829(L)
hepatitis B core antibody ..... 373(L), 829(L)
hepatitis B surface antigen ..... 661(E), 829(L)
HIV-1 antibody ..... 661(E), 829(L)
syphilis ..... 661(E), 829(L)

B

Bacteria
association with K1 antigen 549
growth in platelet concentrates 596
Kell blood group activity 549
red cells, contamination in ..... 372(L), 581
Bar code readers ..... 830(L)
Bis-pyridoxal tetraphosphate hemoglobin 768
Blood bags
plasticizers in ..... 287(E), 292, 358
platelet collection and storage ..... 159, 292, H/S/H(L)
Blood collection
history of 248
needlestick injury during 693
predonation testing ..... 565(E)
Blood components, see under specific component
effect of plastics on 358
sterility ..... 372(L), 596
utilization 139, 298, 471, 473, 761
Blood donors, see donors
Blood filters, see filters
Blood group system
Cromer-related 794, 803
Duffy 31, 233, 505
HLA 31, 311
Kell 642, 711
Kidd 711
Lutheran 304, 711
MNSs 31, 106, 233, 508

P....233
Rh....31, 103, 233, 276(L), 355, 798
Xg....233
Blood grouping, automated....248
Blood processor, see cell separator
Blood substitutes....711, 768, 753(E)
Blood transfusion complications, see transfusion reaction
Blood usage reviews....471(E), 473
Blood utilization....139, 298, 755(E), 761
Blood wastage....139, 677
Bone marrow
cell separators and processing....5(E), 12, 415
cryopreservation of....182
Bone marrow donor registry....778
Bone marrow transplantation
allogenic using cryopreservation....182
comparison with PBSC....323, 522
donors in....317, 778
HLA-matched donor pool size....285(E), 311
processing in....5(E), 12
research opportunities in....711
Books received....469, 583
Book review....4, 87, 112, 178, 468
Borrelia burgdorferi....581, 646

C

Calcium levels in citrated platelets....534
Cancer
adoptive immunotherapy in....170
association with
autologous transfusion....418
DEHP....358
transfusion....236, 500
treatment with PBSC....552
use of blood products in....473
Cell separators
bone marrow processing....5(E), 12, 415
collection of
PBSC....323
platelets....Shan
comparisons of....521
leukapheresis....170
plateletpheresis....288, 521
Chloroquine diphosphate elution of platelet antigens....514
Chromium-51 cell label
comparison with ^{52}Cr....696, 703
double labeling....347
red cell....347
survival studies, red cell....213, 221, 276(L), 347
Chromium-52 cell label, red cell
comparison with ^{125}I and ^{51}Cr....696, 703
posttransfusion recovery estimates....703
volume estimations....696, 703
Chronic granulomatous disease....421
Citrate anticoagulants, effect on platelets....534
Classical pathway of complement activation....803
CMV, see cytomegalovirus
Coagulation factors, see individual factors
Compatibility testing
algorithms in....95(E)
immediate-spin....84(L), 95(E), 99
LISS reagent in....686
of platelets....135, 193(E), 201
PEG reagent in....218, 686, 750(L)
use of computer....95(E), 99, 830(L)
Complement
activation pathways....803
clearance of coated cells....347
role in PNH....663(E), 803
Component, see under specific blood product
Computer, use in compatibility testing....95(E), 99
Computerization of blood bank....830(L)
Confidential unit exclusion....81, 823
Conflict of interest....751(L), 665(E)
Cord blood, Th activation....635
Corrections....58, 340
Cost containment in health care....471(E)
Cost-effective analysis....193(E), 201
CPDA-1, effect on MLC....41
Cromer-related antigens....794, 803
Crookston, Marie....200
Crossmatch, see compatibility testing
Cryogel formation....165
Cryoprecipitate
plasma exchange donation of....332
research opportunities in....711
therapeutic use....473
Cryopreservation, see individual component
Cytapheresis, see under apheresis, specific cell
Cytomegalovirus (CMV)
donor antibody status, geographic variability....278(L), 279(L)
infection after transfusion....278(L), 279(L), 667
pretransfusion screening of neonatal recipients....830(L)
prevention by white cell depletion....757
risk in neonatal transfusion recipients....278(L), 279(L)
use of FDCs in....278(L), 279(L)

D

DAT, see antiglobulin test
DDAVP, see 1-deamino-8-D-arginine vasopressin
1-deamino-8-D-arginine vasopressin (DDAVP)
donor safety with use of....371(L)
use in FVIII production....332, 371(L)
Decision analysis....661(E), 743
DEHP, see di-(2-ethylhexyl) phthalate
Delayed transfusion reactions, see transfusion reactions
Desmopressin acetate, see 1-deamino-8-D-arginine vasopressin
Detailed instructions for authors....88
Diagnosis-related groups (DRGs)....298, 755(E), 761
Di-(2-ethylhexyl) phthalate (DEHP)....287(E), 292, 358
Diltiazem, platelet storage in....153
Di-n-decyl phthalate....292
2,3 diphosphoglycerate (2,3 DPG)....226
Direct antiglobulin test (DAT), see antiglobulin test
DNA polymerase....189(E)
DNA probes, in parentage testing....477
Donors
anemia in....268
apheresis, safety during....424
attitudes in....362, 401
autologous
cancer and transfusion of....418
collection schedule....676
crossover of units....373(L), 821, 829(L)
discard of units from....661(E), 743
Italian....829(L)
screening of
alanine aminotransferase....829(L)
hepatitis B core antibody....373(L), 829(L)
hepatitis B surface antigen....661(E), 829(L)
HIV-1 antibody....661(E), 829(L)
VDRL....661(E), 829(L)
bone marrow
attitudes in....317
HLA-matched pool size....311
recruitment of....778
comparison between autologous and homologous....821, 829(L)
confidential unit exclusion....81, 823
deferral....259, 261, 268, 362, 823, 829(L)
directed
comparison with homologous....655(L), 821
controversy over....65, 70
crossover of....655(L), 821
risk of
HDN....620
hepatitis A....827(L)

transfusion-transmitted diseases .....65, 655(L), 827(L)
education of .....276(L)
HLA-matched pool, size of .....285(E), 306
HIV-1, reduction by filtration 460
HTLV-I follow-up and notification .....1(E)
iron
stores in .....259, 261, 286, 829(L)
supplementation of .....259, 261, 829(L)
mood states 27
patient-related 620
predonation ALT testing .....565(E)
reduction of HIV by filtration 460
reentry protocol 365
risk factors for HIV .....84(L)
safety
during apheresis 521
with lowered hemoglobin standard .....259, 261, 829(L)
with use of DDAVP .....371(L)
screening
alanine aminotransferase .....17, 277(L), 565(E), 750(L), 751(L)
cytomegalovirus .....278(L), 279(L)
hemoglobin .....259, 261, 268, 829(L)
hepatitis B core antibody .....230, 277(L), 373(L), 750(L)
hepatitis B surface antigen .....276(L)
history for high-risk activities .....276(L), 362, 823
HIV-1 antibody .....265, 276(L), 365, 572
HIV-2 368
HTLV-1 antibody .....1(E), 7, 372(L), 746
IgA .....464(L)
surrogate tests
FDA regulations .....750(L)
in Japan .....277(L)
self-deferral .....81, 276(L), 823
use of DDAVP in .....371(L)
Donor-specific transfusions 789
DRGs, see diagnosis-related groups
Duffy blood group system 31, 233, 505

E

Editor, founding 246, 248
EDTA, inhibition of anti-A_1 .....84(L)
Education
efforts in
blood component wastage 139
HIV-1, risk activities .....276(L)
physician 139
transfusion medicine .....438, 558(L)
EIA, see enzyme-linked immunoassay
Enzyme-linked immunoassay (EIA)
HIV-1 antibody .....3(E), 75, 78
Epidemiology, HTLV-I 746
Epstein-Barr virus 196
Erythropoietin 46
Ethics .....186(L), 665(E), 751(L)
Ethlyoxaloacetate 226
Exclusion probability, paternity 31

F

Factor V, stability in twice-frozen FFP 600
Factor VIII (FVIII)
cryogel formation 165
effect of
citrate anticoagulants in cryogel formation 165
pasteurization 208
inhibitors
and AIDS 447
research opportunities 711
plasma exchange donation 33
production, new methods .....466(L)
research opportunities in 711
stability in twice-frozen FFP 600
T4 helper cells 447
use of DDAVP .....332(L), 371(L)
yield .....466(L)
Factor IX concentrate, research opportunities in 711
FDA regulations .....750(L), 661(E)
FFP, see fresh-frozen plasma
Fibrinogen 165
Fibronectin 165
Ficoll-hypaque .....5(E), 12, 491
Filters
CMV removal 757
comparison of for white cell removal 590
HIV reduction 460
white cell removal .....186(L), 411, 460, 496, 562(L), 568(E), 590, 651, Sirch, Kooy
Filtration of plasma 341
Flow cytometry
immune globulin classification 549
white cell quantification 651
Fraudulent data .....665(E)
Fresh-frozen plasma (FFP)
complication of infusion .....86(L)
research opportunities 711
twice-frozen 600
use of 473

G

Gammaglobulins, preparation 629
Gene therapy
research opportunities 711
treatment
of hemoglobinopathies 812
of metabolic disorders 812
Genetics of complement system 803
Giblett, Eloise 200
Glycophorins 106
Glycoproteins
red cell membranes 794, 803
research opportunities 711
Glyoxalate 226
Gm system, in parentage testing 31
Gradient
ficoll-hypaque .....5(E), 12, 491
phthalate ester 221
Graft-versus-host disease
research opportunities 711
transfusion and 544
Granulocyte
activation during cytopheresis 424
research opportunities 711
use in chronic granulomatous disease 421
Greenwalt, Tibor J 246

H

Haptoglobin 31
HBV, see hepatitis B virus
HDN, see hemolytic disease of the newborn
Health care workers, safety of 693
Health policy .....287(E), 358
Hemapheresis, research opportunities in 711
Hematopoietic growth factors
erythropoietin 46
rhGM-CSF .....654(L)
Hematopoietic stem cells
collection with cell separator 323
comparison with bone marrow transplantation 323, 552
in gene therapy 812
research opportunities in 711
use in Hodgkin's disease 323
Hemodilution, research opportunities in 711
Hemoglobin, crosslinked .....753(E), 768
Hemoglobinopathies, treatment with gene therapy 812
Hemoglobin solution 768

Hemoglobin standard, in donors .....259, 261, 268, 829(L)
Hemolysis, associated with complement 803
Hemolytic disease of the newborn (HDN).....355, 465(L), 620, 798
Hemophilia, see also individual coagulation factors
AIDS and FVIII inhibitors in.....447
and HBV-2 in Italy .....558(L)
HIV-1 transmission, risk of 265
use of pasteurized FVIII in 208
Hepatitis A virus .....827(L)
Hepatitis B virus (HBV)
core antibody testing .....230, 277(L), 373(L), 750(L)
employee safety 693
inactivation of 711
surface antigen testing.....276(L)
Hepatitis B virus–type 2 .....558(L)
Hepatitis, non-A,non-B.....230, 277(L), 750(L), 751(L)
History, tranfusion medicine.....248, 355, 753(E)
HIV-1, see human immunodeficiency virus type 1
HIV-2, see human immunodeficiency virus type 2
HLA
antibodies and HIV-1 antibody testing.....119
antigens
quantitation on platelets and in plasma 328
donor pool size for
bone marrow transplantation 311
plateletpheresis 306
-matched platelets .....193(E), 201, 285(E), 306
role in alloimmunization 328
typing for paternity testing 31
Hodgkin's disease 323
HTLV-I, see human T-cell lymphotropic virus type 1
HTLV-III, see human immunodeficiency virus type 1
Human immunodeficiency virus type 1 (HIV-1)
antibody, correlation with self-deferral 81, 823
antibody, tests for
comparisons of.....3(E), 75, 78
false results in.....75, 78, 119
long-term follow-up 365
Western blot 365
cross-reactivity with HIV-2 368
educational efforts in .....276(L)
employee safety and.....693
high-risk activities in blood donors .....276(L), 362
inactivation of 148
infectivity of 148
polymerase chain reaction .....189(E), 265
positive DAT in .....465(L)
reduction by filtration 460
risk factors, in French donors, for .....84(L)
risk in transfusion recipients 113
seroprevalence in
donors 572
recipients of unscreened blood.....113
transmission, heterosexual 265
Human immunodeficiency virus type 2 (HIV-2)
cross-reactivity with HIV-1 368
seroprevalence in
France 368
Spain.....749(L)
transmission.....749(L)
Human T-cell lymphotropic virus type I (HTLV-I)
antibody .....1(E)
antibody tests for
comparisons of .....7, 372(L)
Western blot 7
epidemiology 746
in thalassemia.....561(L)
seroprevalence in donors in Japan .....372(L)
Human T-cell lymphotropic virus type III, (HTLV-III), see human immunodeficiency virus type 1
Hydrocortisone and red cell agglutination.....559(L)
Hydroxyethyl starch, use in leukapheresis 421
Hypercholesterolemia .....283(E), 341

I

Immune globulin
classification, flow cytometry.....549
HIV inactivation in manufacturing of.....629
IgA
antibody 337
bacteria-induced red cell antibodies.....549
genes.....337
methods for detection.....464(L)
research opportunities 711
Immune modulation and transfusion
carcinoma of breast 500
CMV infection 667
GVHD.....544
in AIDS 236
plasma factors.....41
postoperative infections.....456
research opportunities 711
role of major and minor histocompatibility antigens.....789
Immunoadsorbents 135, 514
Immunoblotting 106
Immunology, research opportunities in.....711
Indium-111 labeling
platelets 524, 689, 783
red cells, survival studies 143
Infections and transfusion 236, 456
Information for authors 88
Instructions for authors, detailed.....88
Interleukin-2.....170, 491
International Classification of Diseases .....755(E), 761
Intraoperative autologous transfusion.....711
In utero transfusion 179
Iron stores in donors .....259, 261, 268, 829(L)
Irradiation
gamma, effect on red cell potassium level .....185(L), 749(L)
ultraviolet, effect on
lymphocytes 379
platelets .....377(E), 379, 450
Ixodes dammini 581, 646
Ixodes nicinis 646
Ixodes pacificus 581, 646
Ixodes scapularis 646

K

Kell
association with gram-negative bacteria.....549
association with *Morganella morgani* 549
blood group system.....642, 711
k :dd, blood group system 711
K_{mod} phenotype 642

L

LAK, see lymphokine-activated killer cells
Leukapheresis 170, 421, 424, 491
Leukocyte, see white cell
Levine, Philip 355
Licensure of blood collection facilities .....661(E)
Linkage analysis 304
LISS, see low-ionic-strength solution
Liver transplantation, blood use in 396
Low-ionic-strength solution (LISS) antiglobulin test.....686
L-phenylalanyl-L-alanine.....226
Lutheran, blood group system 304, 711
Lyme disease 581, 646
Lymphadenopathy-associated virus, see human immunodeficiency virus type 1
Lymphocytes, effect of ultraviolet irradiation 379
Lymphokine-activated killer (LAK) cells
collection and processing.....170, 491
in treatment of malignancy 170

M

Major histocompatibility complex (MHC)
research opportunities in 711
role in immune modulation 789
Membrane attack complex 803
Metabolic disorders, treatment with gene therapy 812
MHC, see major histocompatibility complex
Minor histocompatibility complex 789
Mixed lymphocyte culture (MLC) 41, 391
MLC, see mixed lymphocyte culture
MNSs system 31, 106, 233, 508
Monoclonal antibodies
anti-c ....464(L)
impact in blood group serology 58, 340
production ....191(E), 196
reagent use ....58, 106, 187(L), 191(E), 340, 464(L), 798
research opportunities 711
role in AIHA ....191(E), 196
Monocytes, activated 170
Monocyte monolayer assay, antibody detection ....465(L)
Mood states, in donors 27
Morganella morganii 549
Multiple sclerosis, use of plasma exchange in 610

N

Needlestick injury 693
Neonatal transfusions
and risk of CMV infections ....278(L), 279(L), 830(L)
red cells, gamma irradiation and potassium levels in ....185(L), 749(L)
Neutropenia, treatment with rhGM-CSF ....654(L)
Non-A,non-B hepatitis ....750(L), 751(L)

O

Opponent/affective process 27
Oxalate 226

P

Papain 508
Parentage testing
limitations of ....280(L)
use of DNA probes in 477
with an absent mother 31
Paroxysmal nocturnal hemoglobinuria (PNH) ....663(E), 681
Paternity index ....280(L), 281(L), 477
PBSC, peripheral blood stem cells; see hematopoietic stem cells
PCR, see polymerase chain reaction
PEG, see polyethylene glycol
PEP, see phosphoenolpyruvate
Phosphoenolpyruvate (PEP) 614
Plasmapheresis
therapeutic
removal of liproprotein ....283(E), 341
serum protein levels in ....561(L)
Plasma derivatives, research opportunities 711
Plasma exchange
complications in ....97(E), 124
donation of cryoprecipitate and platelets 332
therapeutic
complications in ....97(E)
in multiple sclerosis 610
removal of lipoprotein ....283(E), 341
venous access in 610
Plasma filtration ....283(E), 341
Plasma fractionation 165
Plasma proteins, research opportunities 711
Plasticizers ....287(E), 292, 358
Plastics, effect on components 358
Platelet
aggregation response
after freezing 539
during storage 153, 528
alloimmunization ....377(E), 379, 450, 654(L)
alpha granule secretions 539
and cryogel formation 165
antibodies
detection ....193(E)
elution of 514
in neonatal alloimmune thrombocytopenia 129
specific
Bak^a 129
PI^{A1} 129
antigens
ABO 135, 384, 514
frequency among Koreans 708
retention after storage 405
compatibility testing ....135, 193(E), 201, 405, 514
concentrates
calcium levels in 534
collection
during plasma exchange 332
with PVC bags ....159, 292, H/S/H(L)
cryopreservation of 539
preparation
after extended holding time 689
from buffy coats 605
using cell separators 288, 626, 783
quality control of 273
storage and preservation
aggregation after 153
bacterial contamination in 596
beyond 5 days 605
counts during ....H/S/H(L)
effect of plasticizers 292
following ultraviolet irradiation ....379, 377(E)
HLA antigens in 328
in
citrate anticoagulants 534
diltiazem 153
glucose-free crystalloid medium 605
plasma 528, 783
prostaglandin derivative 153
PVC bags ....159, 292, H/S/H(L)
metabolism during 288, 292
morphology changes in ....36, 153, 159, 528, H/S/H(L)
of pooled platelets 390
pH in ....153, 159, H/S/H(L)
response to platelet activating factor 528
retention of antigen reactivity 405
survival
after extended holding time 689
after white cell depletion 411
following washing 524
in a prostaglandin derivative 153
swirling patterns in 36
thromboxane generation 539
washing 524
white cell-depleted ....186(L), 411, 562(L), 757, 774
freezing damage and size 539
refractoriness ....193(E), 201, 568(E)
research opportunities in 711
storage lesion 534
survival 159, 273, 288, 384, 390
transfusion, effect of ABO compatibility 384
ultraviolet irradiation ....377(E), 379
use ....193(E), 201, 473
Plateletpheresis
HLA-matched donor pool size ....285(E), 306
preparation and storage
in plasma 783
using a cell separator 288, 521
PNH, see paroxysmal nocturnal hemoglobinuria
Polyagglutination of red cells 635
Polyethylene glycol (PEG) ....218, 686, 750(L)

Polymerase chain reaction (PCR) ....189(E), 265
Polyvinylchloride (PVC) platelet bags ....159, 292, H/S/H(L)
Postoperative infection and transfusion 456
Potassium levels, in gamma-irradiated blood ....185(L), 749(L)
Predonation testing ....565(E)
Preoperative collection of autologous blood 676
Probability
  in determining autologous unit discard 743
  in paternity testing calculations ....31, 280(L)
  of immunization to antigens 620
Propidium iodide 651, 774
Prostaglandin derivative, platelet storage 153
Protease inhibitors, research opportunities in 711
Protein levels (serum), in plasmapheresis ....561(L)
PVC, see polyvinylchloride

Q

Quality control, platelets, noninvasive 273, 390

R

Reagents
  affect on antibody by EDTA in ....84(L)
  anti-D, chemically modified ....559(L), 560(L)
  monoclonal antibodies ....58, 106, 191(E), 196, 340, 464(L), 798
  noncellular immunoadsorbents 135, 514
  PEG ....218, 686, 750(L)
  reticulocyte-rich red cell preparation ....560(L)
Recombinant human erythropoietin 711
Recombinant human granulocyte-monocyte colony-stimulating factor (rhGM-CSF) ....654(L)
Recruitment of bone marrow donors 778
Red cell
  agglutination ....559(L)
  aggregation, false 23
  and cancer 500
  and graft-versus-host disease 544
  bacteria-induced antibodies 549
  bacterial contamination of ....372(L), 581
  clearance 347
  donor-specific transfusions 236
  effect of gamma irradiation ....185(L), 749(L)
  freezing 213, 429
  genes
    In(Lu) 711
    LU 304
    Rⁿ 798
    SE 304
  hemolysis due to complement 803
  incompatibility 396
  Indium-111 label 143
  in utero transfusion 179
  mass, in donors 821
  membranes, binding by vancomycin 23
  papain-treated 508
  phenotyping
    in parentage testing 31
    monoclonal antibodies and 58, 340
    use of chemically modified anti-D ....559(L), 560(L)
  preparation
    of reticulocyte-rich cells ....221, 560(L)
    research opportunities in 711
  preservation
    effect of additives 226
    in SAGM 614
  role of
    ADSOL 41
    2,3 DPG 226, 711
    oxalate 226
  rejuvenation by PEP 614
  storage
    and effect on tumor cells 418
    methemoglobin formation 614
    research opportunities in 711
    temperature 213, 429
    time 213, 429, 496
  substitutes ....711, 753(E), 768
  survival
    after freezing 213, 429
    of antibody-sensitized cells ....276(L)
    of reticulocyte-rich cells 221
    studies ....143, 276(L), 696, 703
  Th activation 635
  tumor cells in 418
  use 396, 473
  washed, in PNH ....663(E), 681
  washing ....749(L)
  white cell-depleted ....186(L), 460, 496, 590, 651, 757, 774
Reentry protocol for donors 365
Refractoriness to platelet transfusions ....568(E)
Registry
  bone marrow donor 778
  rare donor 248
Regulatory proteins, complement 803
Renal disease, use of blood products 473
Renal transplantation and red cell transfusions 236
Repository of serum 572, 746
Restriction fragment length polymorphism mapping 477
Reticulocyte-rich red cells, preparation of ....221, 560(L)
Retraction ....665(E)
Retroviral vectors 812
Rh, blood group system ....31, 103, 276(L), 355, 798
rhGM-CSF, see recombinant human granulocyte-monocyte colony-stimulating factor
Risk/benefit analysis 821

S

Safety, of health care workers 693
Schedule of optimal preoperative collection of autologous blood 676
Sialoglycoprotein, red cell 106, 508
Stem cells, see hematopoietic stem cells
Sterile connecting device 390
Storage, see individual component
Suprofen 638
Surgery, autologous blood schedule in 676
Survival studies, red cells 143

T

T4 lymphocytes 447
Taq, see *Thermus aquaticus*
Test kits, see assay
Thalassemia and HTLV-I ....561(L)
Thermus aquaticus 812
Thrombocytopenia, neonatal alloimmune 129
Tolmetin 638
TRANSFUSION, journal expansion ....6(E)
Transfusion, see also individual components
  audits ....139, 298, 471(E), 473
  committee ....139, 298, 471(E)
  immune modulation and 41, 456
  immunologic response to 711
  medicine
    and adoptive immunotherapy 170, 711
    curriculum 438
    education in ....139, 438, 558(L)
    ethics in ....186(L), 665(E), 751(L)
    general ....6(E), 248
    historical ....248, 355, 753(E)
    legal issues in ....186(L)
    research opportunities in 711
    use of
      computer technology ....830(L)
      directed donations ....655(L)
  physiology
    research opportunities in 711
    transfusion trigger 711
  practice

algorithms in ....95(E), 298
assessment of ....139, 298, 471(E)
autologous donors 418
cost analysis, platelet crossmatching versus HLA matching.471(E)
individual components
cryoprecipitate 139, 473
fresh-frozen plasma ....86(L), 473
HLA-matched platelets ....193(E), 201
platelets ....139, 193(E), 201, 473
red cell wastage 139, 473
and bacterial infection 236
association with cancer 236, 500
effects on HIV-1 infection 236
intracardiac in utero 179
in patients with digestive diseases ....755(E), 761
intraoperative salvage 711
liver transplantation 396
quality assurance in ....139, 471(E), 473
use of directed donors 65, 70
reaction
febrile ....568(E)
in PNH ....663(E), 681
other ....86(L), 124
research opportunities in 711
-transmitted diseases
and directed donations 655
cytomegalovirus ....278(L), 279(L), 667, 757
hepatitis A ....827(L)
hepatitis B ....248, 276(L)
hepatitis, non-A,non-B ....276(L), 277(L), 751(L)
hepatitis B virus, type 2 ....558(L)
HIV-1 ....113, 148, 276(L), 572, 629, 659(E), 672
HIV-2 629
HTLV-I ....372(L), 561(L)
Lyme disease 581, 646
prevention by filtration ....568(E)
research opportunities in 711
Yersinia enterocolitica ....372(L)
Transplantation
bone marrow
comparison with PBSC 323, 522
cryopreservation 182
donor attitudes in 317, 778
HLA-matched and donor pool size ....285(E), 311
processing ....5(E), 12
liver
blood use in 396
red cell antibody production in 396
renal
association with red cell transfusion 236
research opportunities in 711
role of transfusion in 789
Tropical spastic paraparesis ....1(E)
Tumor-infiltrating cells 170
Typing reagents, anti-D, chemically modified ....84(L)

U

Ultraviolet irradiation
animal model 450
effect on
antigens 450
blood components 450
lymphocytes 379
platelets ....377(E), 379

V

Vancomycin 23
Venous access in plasma exchange 610
Viral inactivation
heat treatment 148
in manufacture of albumin and gammaglobulins 629
research opportunities in 711
Virus removal
by filtration ....460, 568(E)
by white cell removal 460, 757
research opportunities in 711

W

Washed red cells, in PNH ....663(E), 681
Western blot, evaluation and follow-up of atypical reactivity 365
White cell
-depleted components .186(L), 411, 460, 496, 562(L), 568(E), 651, 757, 774
quantitation in WBC-poor components 651, 768
research opportunities 711
Whole blood
and cancer 500
holding time before processing 689
risk of CMV transmission in 757
use of 473
Wiener, Alexander 355

Y

Yersinia enterocolitica ....372(L)

Contributors to Volume 29

A

AABB Think Tank Planning Group ... 711
Adeniran, A. J. ... 768
Adler, S. P. ... 278, 667
Ahmann, D. L. ... 500
Akard, L. P. ... 12
Akkerman, J. W. N. ... 539
Alberti, A. ... 558
Ali, A. M. ... 268
Ali, M. A. M. ... 268
Allen, R. W. ... 477
Altschule, M. D. ... 429
Anderson, W. F. ... 189
Andreu, G. ... 84
Andrzejewski, C. ... 196
Anstee, D. J. ... 106
Aoki, S. K. ... 646
Apuzzo, J. ... 218
Araszkiewicz, P. ... 103
Ascensao, J. L. ... 46
Aster, R. H. ... 128
Atcher, C. ... 778
Atkins, M. B. ... 491
Aubertin, J. ... 84
AuBuchon, J. P. ... 17, 143, 230, 374
Aulmann, H. M. ... 424
Axelrod, F. B. ... 677
Ayoub, M. M. ... 139
Azen, S. P. ... 572

B

Badon, S. J. ... 581
Balfour, H. H., Jr. ... 265
Barberis, G. ... 829
Barbosa, L. H. ... 572
Barin, F. ... 368
Barnes, B. A. ... 84
Baudelot, J. ... 368
Baxter, A. ... 185
Beasley, R. P. ... 113
Beattie, K. M. ... 642
Beatty, P. G. ... 778
Beck, M. ... 830
Bell, W. ... 411
Ben-Bassat, I. ... 473
Benesch, R. E. ... 768
Berg, B. K. ... 783
Berkman, E. M. ... 491, 661
Bernvil, S. S. ... 179
Bertholf, M. F. ... 521
Bertolini, F. ... 605
Besso, N. ... 186
Bettigole, R. E. ... 829
Beutler, E. ... 226
Bierling, P. ... 654
Biswas, R. ... 750
Blajchman, M. A. ... 268
Blanchette, V. ... 201
Blazar, B. R. ... 182
Bliss, B. ... 477
Blumberg, N. ... 236, 514
Bode, A. P. ... 534
Bodensteiner, D. C. ... 651
Boegel, R. ... 415
Boeri, N. ... 84
Boizard, B. ... 798
Bolgiano, D. C. ... 306
Bontempo, F. A. ... 447
Boris, M. B. ... 590
Botha, I. ... 278
Bove, J. R. ... 375
Braman, V. ... 78
Brand, A. ... 377, 757
Bravo, J. R. ... 821
Brecher, M. E. ... 681
Breckler, S. J. ... 401
Breviere, D. ... 84
Briere, R. O. ... 133
Brightman, A. ... 143
Briquel, M. E. ... 372
Brittenham, G. M. ... 821
Brossard, Y. ... 798
Burdin, J. C. ... 372
Burger, D. ... 278
Burkhardt, H. ... 424
Busch, M. ... 746
Busch, M. P. ... 113, 460

C

Cable, R. G. ... 581
Cairns, R. ... 179
Canadian Apheresis Study Group, The ... 124
Canadian Cooperative Multiple Schlerosis Study Group ... 610
Carmen, R. A. ... 496
Carter, C. S. ... 421, 823
Carter, G. R. ... 823
Cash, J. D. ... 371
Cassidy, G. P. ... 429
Castillo, R. ... 549
Cavagnaro, G. ... 829
Cavalletto, D. ... 558
Chamaret, S. ... 368
Chambers, L. A. ... 373
Chaplin, H. ... 134, 590
Cheney, B. A. ... 153
Chernoff, A. I. ... 572, 711
Chiavetta, J. A. ... 81
Cho, H. I. ... 708
Chong, C. ... 496
Chow, M. P. ... 233
Churchill, W. H. ... 761
Cisco, S. L. ... 642
Claas, F. H. J. ... 377
Clare, D. E. ... 524
Clark, J. A. ... 139
Clarke, U. ... 278
Coffin, C. ... 298
Coghlan, G. ... 304
Comte, S. ... 464
Cooper, E. S. ... 112
Corbin, S. A. ... 379
Cordonnier, C. ... 654
Cornell, F. W. ... 396
Cort, S. ... 148
Cortellaro, M. ... 605
Cotte, G. ... 84
Curriculum Committee of the Transfusion Medicine Academic Award Group ... 438
Couroucé, A. M. ... 84
Courouce, A. M. ... 368

D

Daniels, G. L. ... 794
Davey, F. R. ... 41
Davey, R. J. ... 213, 496
de Gast, G. C. ... 757
de Graan-Hentzen, Y. C. E. ... 757
de Korte, D. ... 36
de Verdier, C. H. ... 614
Deeg, H. J. ... 450
Dennis, R. C. ... 429
DePalma, L. ... 421
Devarajan, S. ... 743
Dewanjee, M. K. ... 524
Dock, N. L. ... 41
Dodd, R. Y. ... 230, 374
Domen, R. E. ... 23
Donegan, E. ... 746
Donovan, L. ... 373
Drago, J. ... 165
Drew, H. ... 411
Driss, J. ... 84
Duquesnoy, R. J. ... 405
Durate, C. ... 829
Dzik, W. H. ... 600, 743

E

Edson, J. R. ... 265
Edwards, G. C. ... 17
Edwards, V. M. ... 572
Einarsson, M. ... 148
Eisenstaedt, R. S. ... 558
Ellinger, P. J. ... 134
Eme, D. ... 84
Emerson, C. P. ... 429
Endow, R. ... 460
English, D. ... 12
Epstein, M. ... 473
Estok, L. ... 590

F

Fang, C. T. ... 230
Fang, G. ... 337
Farrar, R. P. ... 590
Fawcett, K. ... 656
Ferguson, D. J. ... 749
Fijnheer, R. ... 36
Filipovich, A. ... 182
Fister, R. D. ... 581
Fong, K. ... 505
Forstrom, L. A. ... 524
Frank, T. S. ... 119
Freed, J. A. ... 655
Freedman, J. ... 201
Frenzke, M. ... 128
Friedman, L. I. ... 584
Fujiwara, H. ... 372
Fukada, K. ... 7, 337

G

Gadson, M. ... 119
Gafni, A. ... 201
Galligan, B. R. ... 179
Gallin, J. I. ... 421
Garcez, R. B. ... 496
Garcia-de-Lomas, J. ... 460
Garratty, G. ... 261, 560, 665
Garvey, M. B. ... 201
George, V. ... 273
Giles, C. M. ... 803
Gimble, J. ... 584
Glanz, K. ... 558
Glidden, R. A. ... 27

Goldfinger, D. 70, 656, 677
Goldman, J. 196
Goldsmith, C. H. 268
Goodman, D. B. P. 119
Goodnough, L. T. 821
Goto, S. 292
Grandgeorge, M. 629
Gratama, J. W. 757
Graves, V. 12
Gray, A. D. 429
Greenberg, C. R. 304
Greenwalt, T. J. 248
Gregg, R. E. 341
Gremba, C. 415
Griswold, D. J. 686
Grossman, B. J. 830
Grundbacher, F. J. 750
Gueguen, M. 84, 368
Guillard, A. 84
Gullikkson, H. 783

H

Haake, R. 323
Hahn, L. F. 396
Halagan, N. 317
Hale, W. B. 761
Halkin, H. 473
Hallinen, D. 689
Han, K. S. 708
Hanbury, C. M. 696, 703
Hao, S. 761
Hasegawa, I. 292
Haun, M. 464
Heal, J. M. 236, 514, 596
Heaton, A. 159, 689, 828
Heaton, W. A. L. 565, 696, 703
Heinz, R. 827
Herman, J. H. 635
Hernandez, F. P. 751
Hess, E. 778
Hirose, M. 544
Hodge, S. E. 620
Högman, C. F. 614
Hoitsma, A. 638
Holland, P. V. 646
Hollingsworth, C. G. 746
Holme, S. 159, 273, 689, 696, 703, 828
Honaker, L. M. 27
Hopsicker, J. S. 265
Houbiers, J. G. A. 757
Howie, R. I. 561
Hseuh, Y. 821
Hu, H. Y. 233
Hu, W. 337
Huart, J. J. 84
Huestis, D. W. 97, 827
Hurd, D. D. 323
Hwang, L. Y. 113

I

Ikuta, M. 794
Imamura, Y. 372
Imberciardori, G. 829
Inaba, S. 7
Issitt, L. B. 396
Issitt, P. 665
Issitt, P. D. 58, 340, 508

J

Jackson, J. B. 265
Jamieson, G. A. 246
Janot, C. 84, 368, 372
Jansen, J. 12
Jansson, B. A. 783
Janvier, D. 464
Jia, H. 337
Johnson, C. L. 486, 642
Jones, E. C. 559
Judd, W. J. 84, 560
Juji, T. 311

K

Kalbfleisch, J. D. 672
Kamiya, T. 292
Kamstra-Halvorson, L. 317
Kanter, M. H. 620
Kantoff, P. W. 812
Kao, K. J. 328, 774
Kariyone, S. 276
Kasper, C. K. 208
Kassapian, S. J. 17
Kasuya, S. 544
Keating, L. J. 259, 821
Keegan, T. 703
Keegan, T. E. 696
Keipert, P. E. 768
Kent, R. S. 86
Kersey, J. H. 5, 182
Kickler, T. S. 411, 635
Kieckbusch, M. E. 500
Kim, S. I. 708
King, M. J. 106
Kiss, J. E. 405
Kiyokawa, H. 7
Kiyokawa, T. 372
Klachko, D. M. 528
Klein, H. G. 170, 711, 823
Klein, M. T. 798
Kleinman, S. H. 572, 746
Kline, L. 584
Kohn, D. B. 812
Kora, S. 292
Kornprobst, M. 798
Kouketsu, K. 292
Kruskall, M. S. 373
Kuentz, M. 654
Kunieda, K. 544
Kunst, V. A. J. M. 638
Kwok, S. Y. 265
Kwong, S. 768

L

Lamberson, R. 12
Lambert, T. 84
Lane, P. K. 113
Lane, T. A. 86, 418
Larson, E. B. 193, 306
Larson, P. 396
Lasky, L. C. 182, 323, 552
Laustriat, D. 84
Lavagna, G. 829
Lawless, J. F. 672
Leavy, M. E. 429
Lee, E. J. 384
Lee, H. 746
Lee, S. 486
Lee, T. D. 233, 337
Lefrere, J. J. 84
LeFrere, J.-J. 465
Leitman, S. F. 170, 341, 421, 823
Lemaire, J. M. 84, 368
Lenes, B. A. 572
Leng, B. S. 496
Leparc, G. F. 362
LePennec, P.-Y. 465, 798
Lewis, J. H. 447
Lewis, M. 304
Lindena, J. 424
Linehan, S. K. 600
Liu, D. 337
Loiacono, B. R. 823
Lyou, J. Y. 233

M

MacPherson, C. R. 468
Maeda, Y. 7
Malecek, A. C. 134
Maniez, M. 368
Marlo, D. 590
Marsh, W. L. 486, 508, 642
Marshall, G. J. 572
Marugan, R. B. 751
Masouredis, S. P. 665
Matsuo, Y. 654
Matsutomo, K. 544
Matsuyama, H. 614
Mattiauda, M. 829
Matz, K. 298
May, R. 278
Mazzara, R. 549
Mazzei, C. 829
McAlpine, P. J. 304
McAvoy, A. T. 268
McCarroll, D. R. 75
McCarthy, L. J. 12
McCombie, N. 165, 288
McCullough, J. 6, 182, 287, 317, 665
McDougal, J. S. 148
McFarland, J. G. 128
McGinniss, M. H. 87
McGlave, P. 182
McGuff, J. 693
McLeod, B. C. 332
McVoy, M. M. 667
Melaragno, A. J. 429
Menitove, J. E. 1
Mesnier, F. 84, 368
Meyer, E. A. 99
Meyer, D. M. 778
Meyer, J. D. 27
Mickey, R. 285
Mier, J. W. 491
Miller, D. T. 534
Mintz, P. D. 521
Miyazaki, H. 311
Mizutani, Y. 544
Modan, B. 473
Mollison, P. L. 347
Momoda, G. 159, 828
Monos, D. S. 119
Monteagudo, J. 549
Moore, S. B. 500, 755
Moreno, A. 751
Morgan, L. K. 134
Morgan, R. A. 189
Morishima, Y. 292
Morlat, P. 84
Moroff, G. 273, 689
Morris, J. W. 280, 281
Morris, P. J. 789
Morrison, W. J. 528
Mosley, J. W. 572, 746
Mou, L. L. 233
Mouillot, L. 368
Mozes, B. 473
Mudde, G. C. 757
Mueller, K. 508
Mullin, A. 514

Murphy, P. J. 596
Murray, S. A. 561

N

Nagaya, M. 544
Naiman, R. 365
Nair, R. C. 124
Nance, S. J. 560
Napychank, P. 390
Nasr, O. 84
Nelson, E. J. 213, 221, 496
Nemo, G. J. 572, 746
Ness, P. M. 358, 411, 635
Nicod, A. 84
Niehoff, J. 429
Niklasson, F. 614
Niland, J. C. 572
Ninomiya, K. 277
Nishimura, Y. 372
Noel, L. 84, 368
Noma, A. 544
Norman, G. L. 572
Norolle, F. 654
North, M. L. 84, 368
Noseworthy, J. H. 610
Nusbacher, J. 81, 365

O

Oberman, H. 665
Oberman, H. A. 560, 751
Oda, G. 464
Odom, D. G. 153
O'Fallon, J. R. 500
Ohto, H. 276, 277, 654
Okochi, K. 7
Okubo, Y. 794
Olson, W. P. 86
Operskalski, E. A. 572, 746
Orlina, A. R. 465
Otsuka, S. 544
Owens, E. A. 332
Oyen, R. 486

P

Pacini, D. 373
Page, P. L. 65
Pagliaro, P. P. 559
Pall, D. 411
Palmer, D. 165
Pamphilon, D. H. 379
Papaevangelou, G. 561
Parks, W. P. 746
Patel, S. 562
Patten, E. 562
Paysant, J. 464
Pearson, A. 477
Pelloquin, F. 629
Pepkowitz, S. H. 677
Pereira, A. 549
Perenius, L. 148
Perkins, H. 572, 665
Perkins, H. A. 460
Perkins, J. T. 465, 505
Peterman, T. A. 659
Pietersz, R. N. I. 36
Pikul, F. J. 590
Pindyck, J. 572
Pineda, A. A. 283, 524
Pitlick, F. 572
Pivacek, L. E. 429
Pleban, P. 696, 703
Pohl, B. A. 31
Polansky, M. 558
Politis, C. 561
Pontisso, P. 558
Poole, J. 106
Popovsky, M. A. 373, 558, 693
Pouliquen, A. 84
Preiksaitis, J. K. 278
Prystowsky, M. B. 119
Punsalang, A. 596

Q

Quigley, R. L. 789

R

Rabin, B. I. 486, 642
Ragni, M. V. 447
Ramsay, N. K. C. 182
Ramsey, G. 396, 405
Ranzi, M. L. 605
Rasheed, S. 572
Rathbun, E. J. 213
Rawal, B. D. 460
Rearden, A. 187
Rebulla, P. 605
Redman, C. M. 486
Reisling, M. J. 686
Reverter, J. C. 549
Reviron, M. 464
Ribera, A. 749
Riccardi, D. 605
Rich, E. 298
Richard, D. 84
Rico, P. B. 638
Riemens, M. I. 539
Riibner, M. A. 600
Rivers, S. 827
Rivet, C. 185
Roberts, S. 390
Rochant, H. 654
Rock, G. 124, 165, 185, 288, 371, 466, 626, 749
Roeckel, I. E. 276
Rogers, G. 317
Roos, D. 36
Rosenfeld, C. S. 415
Rosenfield, R. E. 355
Rosse, W. F. 663
Rouger, P. 465, 798
Roumeliotou, A. 561
Rousell, R. H. 208
Rouzaud, A.-M. 465
Rouzioux, C. 368
Rovira, M. 549
Rubin, R. J. 358
Ryan, T. 491

S

Saccone, F. 829
Saji, H. 337
Saji, S. 544
Salamon, D. J. 405
Salmon, C. 798
San Roman, A. L. 751
Sandler, S. G. 230
Sannerud, K. J. 265
Saporito, C. 465, 505
Sassetti, R. J. 332
Sato, G. 544
Sato, H. 7
Saunders, J. 379
Schifano, J. V. 179
Schiff, E. R. 746
Schiffer, C. A. 384
Schmidt, P. J. 95, 362, 468
Schnitzer, J. 761
Schoendorfer, D. 165
Schwadron, R. 460
Schwartz, R. S. 208
Scornik, J. C. 774
Scott, E. 317
Scott, J. P. 332
Sebens, F. W. 757
Selbing, A. 179
Senack, E. 626
Senior, M. B. 119
Seno, T. 794
Shadduck, R. K. 415
Shanwell, A. 783
Shear, J. M. 749
Sherman, L. A. 711
Shigeta, K. 276
Shimizu, T. 292
Shirey, R. S. 635
Shriver, K. 572
Shukla, S. D. 528
Shulman, I. A. 99
Shumak, K. H. 610
Sigmund, K. E. 642
Silberstein, L. E. 196
Silvergleid, A. J. 362
Simon, T. L. 221, 438, 496
Simonneau, M. 84
Sinakos, Z. 561
Sinclair, M. 559
Sirchia, G. 605
Slade, B. A. 830
Slater, J. L. 686
Slichter, S. J. 193, 306, 778
Smetana, D. R. 830
Smilovici, W. 84, 368
Smith, D. J. 153
Smith, J. A. 323
Smith, J. W. 341
Sninsky, J. J. 265
Snyder, E. L. 390, 568
Sohmer, P. 221
Sohmer, P. R. 496
Sommerfeld, U. 424
Soriano, V. 749
Sosa, J. C. E. 751
Sosler, S. D. 465, 505
Spitalnik, S. L. 196
Stack, G. 390
Starzl, T. E. 396
Steane, E. A. 178
Steiner, E. A. 560
Stella, M. 78
Strand, R. 317
Streiff, F. 372
Stroncek, D. 317
Stuart, M. 746
Sun, C.-F. 463
Surgenor, D. M. 761
Sutton, D. M. C. 124
Svensson, L. A. 783
Swisher, S. N. 4
Szymanski, I. O. 103

T

Tagariello, G. 558
Takahashi, K. 311
Takakura, F. 7
Takatsuki, K. 372
Takeuchi, H. 544
Tamura, Y. 292
Tandy, N. P. 379
Tartter, P. I. 456
Taswell, H. F. 681

Taylor, P. E. 746
Tedrow, H. 415
Tegtmeier, G. E. 278
Ten Bokkel Huinink, D. 486
The, T. H. 757
Theuriere, M. 508
Thorn, R. M. 78
Tilzer, L. 830
Tittley, P. 165, 288, 626
Toffaletti, J. 534
Tokunaga, K. 7
Tomasulo, P. A. 572, 746
Tor, J. 749
Toy, P. 572
Traldi, A. 558
Transfusion Safety Study Group 572, 746
Trichopoulou, E. 561

U

Unger, P. J. 465
Unrau, L. 559

V

Valeri, C. R. 429
Van Buren, N. 182
van Dijk, B. A. 638
van Heugten, J. G. 539
van Loon, A. M. 757
van Prooijen, H. C. 539
van Rood, J. J. 377
Van Schoonhoven, P. 471
Vance, R. P. 186
Vandervoort, M. K. 610
Velasco, C. 86
Veneroni, G. 559
Verdonck, L. F. 757
Vernant, J. P. 654
Vliet, W. C. 41
Voak, D. 191
Vora, S. 226
Vyas, G. N. 113, 460

W

Wahl, C. M. 635
Waldman, A. 572
Walker, R. H. 31
Wall, A. 81
Wallace, E. L. 761
Ward, J. W. 659
Wartick, M. G. 75
Wasi, S. 464, 561
Weisdorf, D. J. 182
Welch, H. G. 193
Wenz, B. 186, 218
West, C. 226
Whitley, P. 689
Wiggins, E. C. 401
Wildgen, M. 590
Wilkinson, J. S. 17
Willemze, R. 757
Williams, L. 23
Wilson, J. 405
Wiltbank, T. B. 75
Winkler, M. M. 642
Winslow, R. M. 753
Wojtyniak, L. S. 686
Wood, K. J. 789
Wren, M. R. 508
Wu, G. 337

Y

Yamaguchi, H. 794
Yamaguchi, K. 372
Yeston, N. 429
Yi, A. 78
Yoshimura, K. 337
Young, P. J. 196
Yung, C. H. 233

Z

Zamora, C. 751
Zanjani, E. D. 46
Zelinski, T. 304
Zhang, Q. 337
Zillmer, E. A. 27
Zmijewski, C. M. 119
Zuck, T. W. 3
Zylstra, V. W. 524